Skip to main content
COVID-19 In Vitro Diagnostic Devices and Test Methods Database

COVID-19 In Vitro Diagnostic Medical Device - detail

Flowflex SARS-CoV-2 Antigen Rapid Test

Manufactured by Acon Biotech (Hangzhou) Co., Ltd, China - https://www.aconbio.com/ 

Device identification number
1457
CE Marking
Yes
HSC common list (RAT)
Yes
Format
Lab-based, Near POC / POC
Physical Support
Cassette, Lateral flow
Target type
Antigen
Targets
nucleocapsid protein,
Specimen
Nasal swab, Nasopharyngeal swab
Cross-reactivity (pathogens tested)
SARS-CoV
Lineages detected
A.23.1 AT.1 B.1.1.7 (Alpha), B.1.351 (Beta), B.1.427 (Epsilon), B.1.429 (Epsilon), B.1.525 (Eta), B.1.526 (Iota), B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.617.3 B.1.621 (Mu), P.1 (Gamma), P.2 (Zeta), P.3 (Theta), C.37 (Lambda), B.1.616
Commercial Status
Commercialised
Last Update
2022-04-20 12:09:38 CET
Comments
N/A
Assay Type
Immuno-Antigen
Rapid Diagnostic
Yes
Reader Required
No
Method
Immunochromatography
Measurement
Qualitative
Time
15 minutes
Subclass
Membrane-based
LOD
160 TCID50/ml
Calibration
Not evaluated
Crossreactivity
Evaluated
Fp
0.45 % (2 out of 435 (Nasal Swab))
Fp
0.56 % (1 out of 176 (Nasopharyngeal Swab))
Fn
2.94 % (5 out of 170 (Nasal Swab))
Fn
2.43 % (3 out of 123 (Nasopharyngeal Swab))
Precision
Evaluated
Accuracy
98.7 % (Nasopharyngeal Swab)
Accuracy
98.8 % (Nasal Swab)
Reproducibility
Evaluated
Robustness
Evaluated
Clinical Sensitivity
97.1 % (Nasal Swab)
Clinical Sensitivity
97.6 % (Nasopharyngeal Swab)
Clinical Specificity
99.5 % (Nasal Swab)
Clinical Specificity
99.4 % ( Nasopharyngeal Swab)
Type of antigen
Nucleocapsid protein

The database contains publicly available In Vitro Diagnostic Medical Devices for COVID-19 and it is being updated periodically. Please note that additional performance (as retrieved from manufacturers web pages) is provided only for devices commercially available with CE-IVD mark. Acknowledgements